<DOC>
	<DOC>NCT00055471</DOC>
	<brief_summary>The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer</brief_summary>
	<brief_title>A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 18 years &amp; older Confirmed diagnosis of prostate cancer with bone metastases No more than 2 prior chemotherapy regimens No radiation, chemotherapy or bisphosphonates in the past 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>Metastatic prostate cancer</keyword>
	<keyword>bone metastases</keyword>
</DOC>